Becton Dickinson (NYSE:BDX) is reportedly expected to pay over $1B to settle claims related to the use of its mesh wire ...

Becton Dickinson has agreed to resolve nearly all U.S. lawsuits by people who say they were injured by its hernia repair mesh ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Becton Dickinson ...

Becton Dickinson & Co. closed $25.73 short of its 52-week high ($262.23), which the company reached on October 25th.

I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market ...

BD or Becton, Dickinson and Company announced it has reached an agreement to resolve the vast majority of its existing hernia litigation.Terms of the settlement agreement, which are confidential ...

Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Becton, Dickinson and (NYSE:BDX) from Neutral to Buy. As of September 25, 2024, the average one-year price target for ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Shares of Becton Dickinson & Co. BDX inched 0.44% higher to $238.21 Wednesday, on what proved to be an all-around great ...